IDSA, the American Academy of Neurology (AAN) and the American College of Rheumatology (ACR) are jointly developing a systematic review and clinical practice guideline on treatment of Lyme disease.
The guideline panel held a public comment period last spring requesting input on a project plan that laid the ground work for the new Lyme disease guideline. The panel has published its response
(PDF) to input received during the public comment period.
In addition to representatives from IDSA, AAN, and ACR, the panel also includes representation from the American Academy of Family Physicians (AAFP), American Academy of Pediatrics – Committee on Infectious Diseases (AAP-COID), American Academy of Pediatrics – Section on Emergency Medicine (AAP-EM), American College of Physicians (ACP), Association of Medical Microbiology and Infectious Diseases – Canada (AMMI-CA), Child Neurology Society (CNS), Pediatric Infectious Diseases Society (PIDS), Entomological Society of America (ESA), and European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Members representing the disciplines of cardiology, microbiology, pathology, and a methodologist with expertise in GRADE are also included. In addition, the panel includes a healthcare consumer representative, three patients with confirmed Lyme disease, and a parent of a pediatric patient with confirmed Lyme disease.
After a draft of the full guideline is developed, it will also be posted on the IDSA website for a 45-day public comment period. Additional information on the timing and availability of this draft will be posted to the IDSA website.
Next Article >